

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form PTO-94A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

				Application Number	10/602,220
				Filing Date	6/23/2003
				First Named Inventor	TURPEN
				Art Unit	1652
				Examiner Name	Delia M. RAMIREZ
Sheet	1	of	3	Attorney Docket Number	LSBC-0087-CP07B

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
DK		4,921,902	5/1/1990	HALL, et al.	
		5,316,931	5/31/1994	DONSON, et al.	
		5,401,650	3/28/1995	DESNICK, et al.	
		5,356,804	10/18/1994	DESNICK, et al.	
		5,589,367	12/31/1996	DONSON, et al.	
		5,618,699	4/8/1997	HAMAMOTO, et al.	
		5,955,647	9/21/1999	FITCHEN, et al.	
		5,977,438	11/02/1999	TURPEN, et al.	
		6,033,895	3/7/2000	GARGER, et al.	
		6,042,832	3/28/2000	KOPROWSKI, et al.	
		6,210,666	4/3/2001	MIYAMURA	
ML		6,232,099	5/15/2001	CHAPMAN, et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
DK		EP 0174759	3/19/1986	JAMES, et al.		
		EP 0197809	10/15/1986	DELGRANGE, et al.		
		EP 0672754	9/20/1995	HAMAMOTO, et al.		
		EP 0726312	8/14/1996	EKEZE, et al.		
		WO 92/18618	10/29/92	LOMONOSOFF, et al.		
		WO 95/21248	8/10/1995	FITCHEN, et al.		
		WO 96/02649	2/1/1996	LOMONOSOFF		
		WO 96/12027	4/25/1996	CHAPMAN, et al.		
		WO 96/12028	4/25/1996	TURPEN, et al.		
		WO 97/10353	3/20/1997	RADIN, et al.		
		WO 97/39134	10/23/1997	WILSON, et al.		
		WO 97/49425	12/31/1997	BEEKMAN, et al.		
ML		WO 99/46288	9/16/1999	GARGER, et al.		

Examiner Signature		Date Considered	2/24/06
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Application Number	10/602,220
Sheet	2	of	3	Filing Date	6/23/2003
				First Named Inventor	TURPEN
				Group Art Unit	1652
				Examiner Name	Delia M. RAMIREZ
				Attorney Docket Number	LSBC-0087-CP07B

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
<i>DR</i>		BAKER, et al., "Polyethylenimine (PEI) is a simple, inexpensive and effective reagent for condensing and linking plasmid DNA to adenovirus for gene delivery", <i>Gene Therapy</i> (1997) 4:773-782			
		DAWSON, et al., "A Tobacco Mosaic Virus-Hybrid Expresses and Loses an Added Gene", <i>Virol.</i> (1989) 172:285-292			
		DAWSON, et al., "cDNA cloning of the complete genome of tobacco mosaic virus and production of infectious transcripts", <i>Proc. Natl. Acad. Sci. USA</i> (1986) 83:1832-1836			
		DAWSON, et al., "Modifications of the tobacco mosaic virus coat protein gene affecting replication, movement, and symptomatology", <i>Mol. Plant Pathol.</i> (1988) 78(6):783-789			
		DONSON, et al., "Systemic expression of bacterial gene by a tobacco mosaic virus-based vector", <i>Proc. Natl. Acad. Sci. USA</i> (1991) 88:7204-7208			
		HAMAMOTO, et al., "A new tobacco mosaic virus vector and its use for the systemic production of angiotensin-I-converting enzyme inhibitor in transgenic tobacco and tomato", <i>Bio/Tech.</i> (1993) 11:930-932			
		HAYNES, et al., "Development of a genetically-engineered, candidate polio vaccine employing the self-assembling properties of the tobacco mosaic virus coat protein", <i>Bio/Tech.</i> (1986) 4:637-641			
		JADADISH, et al., "High level production of hybrid potyvirus-like particles carrying repetitive copies of foreign antigens in Escherichia coli", <i>Bio/Tech.</i> (1993) 11:1166-1170			
		KORNREICH, et al., Swiss Prot accession number AGAL_HUMAN, January 1988			
		KREBBERS, et al., "Prospects and progress in the production of foreign proteins and peptides in plants", <i>Plant Protein Engineering</i> , Shewry, et al., Eds., Cambridge University Press, Cambridge (1992) pp. 316-324			
		MURRAY, "Lectin-specific targeting of lysosomal enzymes to reticuloendothelial cells", <i>Methods in Enzymology</i> (1987) 149:25, 39, 41-42			
<i>DR</i>		MURRAY, et al., "Production of Recombinant Human Glucocerebrosidase in Plants", <i>Fed. of American Soc. for Experimental Biology</i> , (April 1996) 10(6):a1126 - already considered in IIDS of 9/17/04			

Examiner Signature	<i>DR</i>	Date Considered	2/24/06
--------------------	-----------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.**

Substitute for form 1449B/PTO				<b><i>Complete if Known</i></b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Application Number	10/602,220
				Filing Date	6/23/2003
				First Named Inventor	TURPEN
				Group Art Unit	1652
				Examiner Name	Delia M. RAMIREZ
Sheet	3	of	3	Attorney Docket Number	LSBC-0087-CP07B

## **NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>JR</i>		TAKAMATSU, et al., "Production of enkephalin in tobacco protoplasts using tobacco mosaic virus RNA vector", <i>FEBS Lett.</i> (1990) 269(1):73-76	
<i>JR</i>		TURPEN, et al., "Malarial epitopes expressed on the surface of recombinant tobacco mosaic virus", <i>Bio/Tech.</i> (1995) 13:53-57	
<i>JR</i>		YUSIBOV, et al., "Antigens produced in plants by infection with chimeric plant viruses immunize against rabies virus and HIV-1", <i>Proc. Natl. Acad. Sci. USA</i> (1997) 94:5784-5788	

Examiner Signature		Date Considered	2/24/06
-----------------------	---	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.**

Substitute for form 1449A/PTO		<b>Complete if Known</b>		
<b>O I P E</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>		Application Number	10/602,220	
		Filing Date	6/23/2003	
		First Named Inventor	TURPEN et al.	
		Art Unit	1652	
		Examiner Name	RAMIREZ, Delia M.	
1	of	5	Attorney Docket Number	
LSBC-0087-CP07B				

## **U.S. PATENT DOCUMENTS**

## FOREIGN PATENT DOCUMENTS

**Examiner  
Signature**



Date Considered

2124106

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Application Number	10/602,220
Sheet	2	of	5	Filing Date	6/23/2003
				First Named Inventor	TURPEN et al.
				Group Art Unit	1652
				Examiner Name	RAMIREZ, Delia M.
				Attorney Docket Number	LSBC-0087-CP07B

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>DR</i>	.	BORK, "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle", <i>Genome Research</i> (2000) 10:398-400	
	.	BOWIE, et al., "Diciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions", <i>Science</i> (1990) 247:1306-1310	
	.	BRADY, "Fabry Disease", <i>Peripheral Neuropathy</i> , 3 <sup>rd</sup> ed., 1169-1178 (1993), W.B. Saunders	
	.	BROUN, et al., "Catalytic plasticity of fatty acid modification enzymes underlying chemical diversity of plant lipids", <i>Science</i> (1998) 282:1315-1317	
	.	CHAPMAN, et al., "Potato virus X as a vector for gene expression in plants", <i>The Plant Journal</i> (1992) 2(4):549-557	
	.	COPPOLA, et al., "Characterization of glycolylated and catalytically active recombinant human $\alpha$ -galactosidase A using a baculovirus vector", <i>Gene</i> (1994) 144:197-203	
	.	CRAMER, <i>American Journal of Human Genetics</i> , (1995) 57(4), published for the American of Human Genetic by the University of Chicago Press	
	.	DESNICK, et al., " $\alpha$ -Galactosidase A Deficiency: Fabry Disease", <i>The Metabolic Bases of Inherited Diseases</i> , Chapter 89, pp. 2741-2784 (1995), McGraw-Hill	
	.	ERICKSON, et al., "BioSynthesis of the Lysosomal Enzyme Glucocerebrosidase", <i>J. Bio. Chem.</i> , (1985) 260(26):14319-14324	
	.	FERRARI, et al., "Cloning and expression of a soluble sialidase from Chinese hamster ovary cells: sequence alignment similarities to bacterial sialidases", <i>Glycobiology</i> , (1994) 4(3):367-373	
	.	FRANK, et al., "Automation of DNA Sequencing Reactions and Related Techniques: A Workstation for Micromanipulation of Liquids", <i>Biotechnology</i> , (1988) 6:1211	
	.	FURBISH, et al., "Enzyme replacement therapy in Gaucher's disease: Large-scale purification of glucocerebrosidase suitable for human administration", <i>Proc. Natl. Acad. Sci.</i> , (1977) 71(8):3560-3563	
<i>DR</i>		FURBISH, et al., "Uptake and Distribution of Placental Glucocerebrosidase in at Hepatic Cells and Effects of Sequential Deglycosylation", <i>Biochimica et biophysica Acta.</i> , (1981) 673:425-434	

Examiner Signature	<i>DR</i>	Date Considered	2/24/06
--------------------	-----------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Application Number	10/602,220
Sheet	3	of	5	Filing Date	6/23/2003
				First Named Inventor	TURPEN et al.
				Group Art Unit	1652
				Examiner Name	RAMIREZ, Delia M.
				Attorney Docket Number	LSBC-0087-CP07B

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
<i>JM</i>	.	GRABOWSKI, et al., "Expression of Functional Human Acid $\beta$ -glucosidase in COS-1 and <i>Sporodoptera frugiperda</i> Cells", <i>Enzyme</i> , (1989) 41:131-142		
	.	GRACE, et al., "Analyses of catalytic activity and inhibitor binding of human acid $\beta$ -glucosidase by site-directed mutagenesis", <i>J. Bio. Chem.</i> (1990) 265:6827-6835		
	.	GRACE, et al., "Analysis of Human Acid $\beta$ -glucosidase by Cite-Directed Mutagenesis and Heterologous Expression", <i>J. Bio. Chem.</i> (1994) 269(3): 2283-2291		
	.	GRACE and GRABOWSKI, "Human Acid $\beta$ -glucosidase: Glycosylation Is Required for Catalytic Activity", <i>Biochemical and Biophysical Research Communications</i> , (1990) 168(2):771-777		
	.	HASKINS, et al., "Alpha-L-Iduronidase Deficiency in a Cat: A Model Mucopolysaccharidosis I", <i>Pediat. Res.</i> (1979) 13:1294-1297		
	.	HOPP, et al., "A Short Polypeptide mark sequence useful for recombinant protein identification and purification", <i>Biotechnology</i> , (1988) 6:1204-1210		
	.	JONSSON, et al., "Biosynthesis and naturation of glucocerebrosidase in Gaucher fibroblasts", <i>Eur. J. Biochem.</i> , (1987) 164:171-179		
	.	KAPLAN, et al., "Phosphohexosyl components of a lysosomal enzyme are recognized by pinocytosis receptors on human fibroblasts", <i>Proc. Natl. Acad. Sci. USA</i> (1977) 74(5):2026-2030		
	.	KENWARD, et al., "Accumulation of Type I Fish Antifreeze Protein in Transgenic Tobacco Is Cold Specific", <i>Plant Mol. Biol.</i> (1993) 23:377-385		
	.	KORNFELD and MELLMAN, "The Biogenesis of Lysosomes", <i>Annu. Rev. Cell Biol.</i> , (1989) 5:483-525		
	.	LEE and RAIKHEL, "Prohevein is poorly processed but shows enhanced resistance to a chitin-binding fungus in transgenic tomato plants", <i>Brazilian J. Med. and Biol. Res.</i> , (1995) 28:743-750		
	.	MIYAMURA, et al., "A Carboxy-terminal Truncation of Human $\alpha$ -Galactosidase A in a Heterozygous Female with Fabry Disease and Modification of the Enzymatic Activity by the Carboxy-terminal Domain", <i>J. Clin. Invest.</i> , (1996) 98(8):1809-1817		
	.	MURRAY, et al., "Production of Recombinant Human Glucocerebrosidase in Plants", <i>Fed. of American Soc. for Experimental Biology</i> , (1996) 10(6):a1126		
<i>JM</i>	.	PARK, et al., "Structure and nucleotide sequence of tomato HMG2 encoding 3-hydroxy-3-methyl-glutaryl coenzyme A reductase", <i>Plant Mol. Biol.</i> (1992) 20:327-331		

Examiner Signature	<i>JM</i>	Date Considered	2/24/06
--------------------	-----------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
				Application Number	10/602,220
				Filing Date	6/23/2003
				First Named Inventor	TURPEN et al.
				Group Art Unit	1652
				Examiner Name	RAMIREZ, Delia M.
Sheet	4	of	5	Attorney Docket Number	LSBC-0087-CP07B

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>DR</i>	.	SCHATZLE, et al., "Molecular Cloning and Characterization of the Structural Gene Coding for the Developmentally Regulated Lysosomal Enzyme, $\alpha$ -Mannosidase, in <i>Dictyostelium discoideum</i> , <i>J. Bio. Chem.</i> (1991) 267(6):4000-4007	
	.	SCHULZ and SCHIRMER, "Principles of Protein Structure", (1979) pp. 14-16, Springer-Verlag, eds.	
	.	SCOTT, et al., "Structure and Sequence of the Human $\alpha$ -L-Iduronidase Gene", <i>Genomics</i> , (1992) 13:1311-1313	
	.	SCOTT, et al., "Human $\alpha$ -L-iduronidase: cDNA isolation and expression", <i>Proc. Natl. Acad. Sci. USA</i> , (1991) 88:9695-9699	
	.	SEFFERNICK, et al., "Melamine Deaminase and Atrazine Chlorohydrolase: 98 percent Identical but Functionally Different", <i>J. Bacteriol.</i> (2001) 183(8):2405-2410	
	.	SHULL, et al., "Enzyme replacement in a canine model for Hurler syndrome", <i>Proc. Natl. Acad. Sci. USA</i> , (1994) 91:12937-12941	
	.	SIJMONS, et al., "Production of Correctly Processed Human Serum Albuminin Transgenic Plants", <i>Biotechnology</i> , (1990) 8:217-221	
	.	SORGE, et al., "Molecular cloning and nucleotide sequence of human glucocerebrosidase cDNA", <i>Proc. Natl. Acad. Sci. USA</i> , (1985) 82:7289-7293	
	.	TAKAMATSU, et al., "Expression of bacterial chloramphenicol acetyltransferase gene in tobacco plants mediated by TMV-RNA", <i>EMBO J.</i> , (1987) 6(2):307-311	
	.	THORNBURG, et al., "Wound-inducible expression of a potato inhibitor II-chloramphenicol acetyltransferase gene fusion in transgenic tobacco plants", <i>Proc. Natl. Acad. Sci.</i> (1987) 84:744-748	
	.	TSUJI, et al., "Nucleotide Sequence of cDNA Containing the Complete Coding Sequence for Human Lysosomal Glucocerebrosidase", <i>J. Bio. Chem.</i> (1986) 261(1):50-53	
	.	VANDEKERCKHOVE, et al., "Enkephalins Produced in Transgenic Plants Using Modified 2S Seed Storage Proteins", <i>Biotechnology</i> , (1989) 7:929-933	
	.	VIERSTRA, "Protein Degradation in Plants", <i>Annual Review of Plant Physiology and Plant Molecular Biology</i> (1993) 44:385-410, Annual Reviews, Inc., Palo Alto, California	
<i>DR</i>	.	VON FIGURA and HASILIK, "Lysosomal Enzymes and Their Receptors", <i>Ann. Rev. Biochem.</i> , (1986) 55:167-193	

Examiner Signature		Date Considered	2/24/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
				Application Number	10/602,220
				Filing Date	6/23/2003
				First Named Inventor	TURPEN et al.
				Group Art Unit	1652
				Examiner Name	RAMIREZ, Delia M.
Sheet	5	of	5	Attorney Docket Number	LSBC-0087-CP07B

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>DR</i>		WARNER, et al., "Photolabeling of the $\alpha$ -Neuraminidase/ $\beta$ -Galactosidae Complex from Human Placenta with a Photoreactive Neuraminidase Inhibitor", <i>Biochem. and Biophys. Res. Comm.</i> (1990) 173(1):13-19	
<i>/</i>		WEISSENBORN, "HMG-CoA reductase and terpenoid phytoalexins: Molecular specialization within a complex pathway", <i>Physiologia Plantarum</i> , (1995) 93:393-400	
		WELLS, "Additivity of Mutational Effects in Proteins", <i>Biochemistry</i> (1990) 29(37):8509-8517	
<i>DR</i>		WITKOWSKI, et al., "Conversion of a beta-Ketoacyl synthase to a malonyl decarboxylase by replacement of the active-site cysteine with glutamine", <i>Biochemistry</i> (1999) 38:11643-11650	

Examiner Signature		Date Considered	2/24/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.